ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,16
-0,69%
Dow Jones
40 699,51
1,21%
DAX
18 518,03
-0,44%
Brent Oil
83,485
-1,01%
Bitcoin
64 661,50
-0,31%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
26/09/201613h00GlobeNewswire Inc.Summit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular DystrophyNASDAQ:SMMTSummit Therapeutics Inc
12/09/201613h00GlobeNewswire Inc.Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy CommunityNASDAQ:SMMTSummit Therapeutics Inc
08/09/201623h07Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
08/09/201613h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2016 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
07/09/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment ConferenceNASDAQ:SMMTSummit Therapeutics Inc
05/09/201613h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016NASDAQ:SMMTSummit Therapeutics Inc
09/08/201613h00GlobeNewswire Inc.Summit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate EzutromidNASDAQ:SMMTSummit Therapeutics Inc
05/08/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at Canaccord Genuity Growth ConferenceNASDAQ:SMMTSummit Therapeutics Inc
20/06/201618h30GlobeNewswire Inc.Summit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile InfectionNASDAQ:SMMTSummit Therapeutics Inc
17/06/201613h00GlobeNewswire Inc.First Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMDNASDAQ:SMMTSummit Therapeutics Inc
16/06/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at JMP Securities Life Sciences ConferenceNASDAQ:SMMTSummit Therapeutics Inc
08/06/201613h00GlobeNewswire Inc.Summit Therapeutics to Host Utrophin R&D Day 15 June 2016NASDAQ:SMMTSummit Therapeutics Inc
06/06/201612h01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SMMTSummit Therapeutics Inc
02/06/201613h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
31/05/201613h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016NASDAQ:SMMTSummit Therapeutics Inc
26/05/201622h17Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:SMMTSummit Therapeutics Inc
25/05/201615h44Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
23/05/201613h00GlobeNewswire Inc.Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM...NASDAQ:SMMTSummit Therapeutics Inc
12/05/201612h06Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:SMMTSummit Therapeutics Inc
12/05/201612h06Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:SMMTSummit Therapeutics Inc
10/05/201613h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016NASDAQ:SMMTSummit Therapeutics Inc
06/05/201613h00GlobeNewswire Inc.Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016NASDAQ:SMMTSummit Therapeutics Inc
28/04/201617h46GlobeNewswire Inc.Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the...NASDAQ:SMMTSummit Therapeutics Inc
28/04/201613h00GlobeNewswire Inc.Summit Announces Further US Patent Granted for CDI Antibiotic RidinilazoleNASDAQ:SMMTSummit Therapeutics Inc
11/04/201613h00GlobeNewswire Inc.Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infe...NASDAQ:SMMTSummit Therapeutics Inc
06/04/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at 15th Annual Needham Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
30/03/201613h00GlobeNewswire Inc.Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients W...NASDAQ:SMMTSummit Therapeutics Inc
29/03/201615h25GlobeNewswire Inc.Summit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole’s Statistical Superiority Over Vancomycin ...NASDAQ:SMMTSummit Therapeutics Inc
15/03/201612h00GlobeNewswire Inc.Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMDNASDAQ:SMMTSummit Therapeutics Inc
10/03/201601h46GlobeNewswire Inc.Summit Announces Ridinilazole Preserves the Gut Microbiome of Patients With C. difficile Infection in Phase 2 TrialNASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

EU
AI
Air Liquide
NYSE
JPM
JP Morgan Chase
EU
BN
Danone
NYSE
MCD
McDonalds
NASDAQ
GOOGL
Alphabet
FTSE
UKX
FTSE 100
EU
PX1
CAC 40
EU
DG
Vinci
EU
PX4
SBF 120
EU
BEL20
Bel 20
EU
AF
Air FranceKLM
EU
VK
Vallourec
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés